ArticleInvestigative ophthalmology & visual science2026
Identification and Validation of Biomarkers in the Development and Progression of Graves' Ophthalmopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Graves' ophthalmopathy (GO) is the most common extrathyroidal manifestation of Graves' disease. This study aimed to identify immune-related genes involved in GO pathogenesis and evaluate their potential as peripheral blood biomarkers for early diagnosis and disease severity assessment. Methods: Bulk RNA sequencing was performed on peripheral blood mononuclear cells from 16 GO patients and six healthy controls. Differential expression, functional enrichment, weighted gene co-expression network analysis (WGCNA), and immune infiltration analyses were conducted. Key genes were validated by quantitative real-time PCR and flow cytometry in independent cohorts. Results: A total of 2858 differentially expressed genes (DEGs) were identified, with significant enrichment in immune-related pathways. Integrating DEGs, WGCNA modules, and pathway analyses identified 90 candidate hub genes. Among these, XAF1, SAMD9L, and CD2 showed high diagnostic accuracy for GO. Notably, only CX3CR1 and IL-7R expression correlated significantly with disease severity; IL-7R was significantly downregulated after immunosuppressive therapy in responsive patients. Flow cytometry confirmed that IL-7R expression in CD4+ T cells and memory B cells was positively associated with GO severity. Conclusions: This study identifies IL-7R and CX3CR1 as novel severity-associated biomarkers in GO, providing insights into its immunopathogenesis and offering potential peripheral blood-based targets for diagnosis, prognosis, and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.